Overall rank by patents
#3,699
Across all tracked assignees
USPTO PatentsView assignee record — 98 granted patents across 13 technology areas, active 2015–2022. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).
The verdict
CureVac holds 98 US patents across 13 technology areas — rank #3,699 of 50,000 tracked assignees.
CureVac AG has been granted 98 US utility patents between 2015 and 2022, placing CureVac AG at rank #3,699 across all assignees tracked by PlainPatent. This portfolio spans 13 distinct Cooperative Patent Classification (CPC) subclasses, averaging 20.3 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a Foreign Corporation, CureVac AG is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 44.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 51 grants, compared with 47 in the 2015–2019 window — a +9% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. CureVac AG's 20.3 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 13 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark CureVac AG against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
International Business Machines Corporation
72,926 patents
Canon Kabushiki Kaisha
34,378 patents
LG ELECTRONICS INC.
32,607 patents
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
Apple Inc.
30,560 patents
QUALCOMM Incorporated
30,354 patents
Intel Corporation
27,498 patents
CureVac AG
98 patents
What this shows CureVac holds 98 patents — placing it at rank #3,699 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
CureVac's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
44 Top 27% higher than 73% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 2 | 2.0% |
| 2016 | 11 | 11.2% |
| 2017 | 10 | 10.2% |
| 2018 | 11 | 11.2% |
| 2019 | 13 | 13.3% |
| 2020 | 15 | 15.3% |
| 2021 | 15 | 15.3% |
| 2022 | 21 | 21.4% |
Top 13 of 13 technology areas
Overall rank by patents
#3,699
Across all tracked assignees
44.1 out of 100
How to use this portfolio
Curevac's 98 grants land it in the top 27% by Innovation Score — but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity — not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
CureVac AG's primary CPC class — all holders and yearly trends
See where CureVac AG ranks among the largest US patent assignees
Browse every CPC technology area by patent activity
The four dimensions behind the Innovation Score
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.